A 419259 trihydrochloride

CAS No. 1435934-25-0

A 419259 trihydrochloride( —— )

Catalog No. M23600 CAS No. 1435934-25-0

A 419259 trihydrochloride is an Src family kinases inhibitor (IC50s: 9 nM, 3 nM and 3 nM for Src, Lck and Lyn).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 61 In Stock
5MG 98 In Stock
10MG 161 In Stock
25MG 302 In Stock
50MG 528 In Stock
100MG 755 In Stock
500MG 1503 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    A 419259 trihydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    A 419259 trihydrochloride is an Src family kinases inhibitor (IC50s: 9 nM, 3 nM and 3 nM for Src, Lck and Lyn).
  • Description
    A 419259 trihydrochloride is an Src family kinases inhibitor (IC50s: 9 nM, 3 nM and 3 nM for Src, Lck and Lyn).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Tyrosine Kinase
  • Target
    Src
  • Recptor
    Lck|Lyn|Src
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1435934-25-0
  • Formula Weight
    592
  • Molecular Formula
    C29H37Cl3N6O
  • Purity
    >98% (HPLC)
  • Solubility
    Water:53 mg/mL (89.53 mM)
  • SMILES
    NC1=C2C(N([C@H]3CC[C@H](N4CCN(C)CC4)CC3)C=C2C5=CC=C(OC6=CC=CC=C6)C=C5)=NC=N1.[H]Cl.[H]Cl.[H]Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Wilson MB, et al. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene. 2002 Nov 21;21(53):8075-88.
molnova catalog
related products
  • WH-4-023

    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.

  • Neochlorogenic acid

    Chlorogenic acid has resistance to the brown rot fungus, may by interfering with fungal melanin production.

  • KX2-391

    KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.